SI9200143B - Method and composition for the prevention of lyme disease - Google Patents

Method and composition for the prevention of lyme disease Download PDF

Info

Publication number
SI9200143B
SI9200143B SI9200143A SI9200143A SI9200143B SI 9200143 B SI9200143 B SI 9200143B SI 9200143 A SI9200143 A SI 9200143A SI 9200143 A SI9200143 A SI 9200143A SI 9200143 B SI9200143 B SI 9200143B
Authority
SI
Slovenia
Prior art keywords
vaccine according
polypeptide
prevention
composition
immunogen
Prior art date
Application number
SI9200143A
Other languages
English (en)
Other versions
SI9200143A (en
Inventor
Ian Livey
Friedrich Dorner
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27419096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI9200143(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of SI9200143A publication Critical patent/SI9200143A/sl
Publication of SI9200143B publication Critical patent/SI9200143B/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (7)

1 Patentni zahtevki 1. Cepivo proti lymski boreliozi, označeno s tem, da obsega imnogen iz skupine ene ali več seroloških oblik pC polipeptida B. burgdorferi v količini, ki je učinkovita za imuniziranje dovzetnega sesalca pred lymsko boreliozo, pri čemer je količina v območju od 1 do 100 pg na imunogen na dozo, in adjuvans.
2. Cepivo po zahtevku 1, označeno s tem, da obsega zmes različnih seroloških oblik ne-denaturiranega pC polipeptida.
3. Cepivo po zahtevku 1 ali 2, označeno s tem, da vsebuje enega ali več antigenov ne-pC B. burgdorferi.
4. Cepivo po zahtevkih 1 do 3, označeno s tem, daje adjuvans aluminijev hidroksid.
5. Cepivo po kateremkoli od prejšnjih zahtevkov 1 do 4, označeno s tem, da je količina v območju od 10 do 50 pg na imunogen na dozo.
6. Cepivo po kateremkoli od prejšnjih zahtevkov 1 do 5, označeno s tem, daje sesalec človek.
7. Cepivo po kateremkoli od prejšnjih zahtevkov 1 do 6, označeno s tem, da je imunogen v homogeni obliki in obsega vsaj 80 m/v% strukturno intaktnega pC polipeptida.
SI9200143A 1991-07-11 1992-07-10 Method and composition for the prevention of lyme disease SI9200143B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72724591A 1991-07-11 1991-07-11
US82416192A 1992-01-22 1992-01-22
US07/903,580 US6221363B1 (en) 1991-07-11 1992-06-25 Vaccine for the prevention of lyme disease

Publications (2)

Publication Number Publication Date
SI9200143A SI9200143A (en) 1993-03-31
SI9200143B true SI9200143B (en) 2001-06-30

Family

ID=27419096

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9200143A SI9200143B (en) 1991-07-11 1992-07-10 Method and composition for the prevention of lyme disease

Country Status (17)

Country Link
US (2) US6221363B1 (sl)
EP (1) EP0522560B2 (sl)
JP (1) JP2611095B2 (sl)
AT (1) ATE198489T1 (sl)
AU (1) AU660178B2 (sl)
CA (1) CA2073486C (sl)
CZ (1) CZ280743B6 (sl)
DE (1) DE69231619T3 (sl)
DK (1) DK0522560T4 (sl)
ES (1) ES2154633T3 (sl)
FI (1) FI107334B (sl)
HR (1) HRP950174B1 (sl)
HU (1) HU219772B (sl)
MX (1) MX9204078A (sl)
NO (1) NO304546B1 (sl)
SI (1) SI9200143B (sl)
SK (1) SK217292A3 (sl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872550B1 (en) * 1991-07-11 2005-03-29 Baxter Vaccine Ag Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
US6303129B1 (en) * 1992-07-28 2001-10-16 Rx Technologies Production of borrelia burgdorferi vaccine, product produced thereby and method of use
PL178775B1 (pl) * 1993-04-29 2000-06-30 Baxter Ag Kompozycja immunogenna, rekombinacyjne sekwencje DNA, rekombinacyjny wektor ekspresyjny, transformowana komórka gospodarza i antygen OspC
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
PT757556E (pt) 1994-04-11 2006-10-31 Wyeth Corp Bacterina borrelia burgdorferi
US6087097A (en) * 1994-05-12 2000-07-11 Mayo Foundation For Medical Education And Research PCR detection of Borrelia burgdorferi
ZA964896B (en) * 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
CN1285608C (zh) * 1995-09-22 2006-11-22 康诺特实验室有限公司 副流感病毒糖蛋白和疫苗
WO1997015600A1 (en) * 1995-10-26 1997-05-01 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Tick (ixodes scapularis) vector saliva-induced lyme disease spirochete (borrelia burgdorferi) antigens as vaccine candidates
US6045804A (en) * 1996-03-07 2000-04-04 Mayo Foundation For Medical Educational Research Method for detecting B. burgdorferi infection
US6716574B2 (en) 1996-05-02 2004-04-06 Dako A/S Osp-C derived peptide fragments
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
GB9811219D0 (en) * 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel process
EP1173577A2 (en) * 1999-04-21 2002-01-23 Boston Medical Center Corporation Prevention, diagnosis and treatment of lyme disease
PT1194559E (pt) * 1999-06-18 2007-01-31 Brook Biotechnologies Inc Grupos de borrelia burgdorferi e borrelia afzelii que causam a doença de lyme em seres humanos
WO2002016421A2 (en) 2000-08-18 2002-02-28 Research Foundation Of The State University Of New York Altered ospa of borrelia burgdorferi
US8277852B2 (en) * 2002-01-25 2012-10-02 Akzo Nobel Surface Chemistry Llc Bioactive botanical cosmetic compositions and processes for their production
US7442391B2 (en) * 2002-01-25 2008-10-28 Integrated Botanical Technologies, Llc Bioactive botanical cosmetic compositions and processes for their production
ES2652603T3 (es) 2004-01-12 2018-02-05 Isp Investments Llc Composiciones bioactivas de plantas de Theacea y procedimientos para su producción y uso
EP1983247A1 (en) 2006-01-19 2008-10-22 Toyo Seikan Kaisya, Ltd. Coupler and fuel cartridge for fuel cell
EP2077856B1 (en) * 2006-11-03 2015-08-12 Intervet International BV Canine lyme disease vaccine
ATE496935T1 (de) 2007-02-22 2011-02-15 Baxter Int Verfahren zur aufreinigung hydrophober proteine
JP2011518338A (ja) * 2008-04-22 2011-06-23 リサーチ ファンデーション オブ ステート ユニバーシティ オブ ニューヨーク ボレリア・ブルグドルフェリ（ｂｏｒｒｅｌｉａｂｕｒｇｄｏｒｆｅｒｉ）の細胞エンベロープタンパク質のアレイ
CN102791727A (zh) * 2009-11-17 2012-11-21 爱贝斯股份有限公司 用于检测莱姆病抗体的肽和方法
DK3549949T5 (da) 2011-04-22 2024-09-02 Wyeth Llc Sammensætninger vedrørende et mutant Clostridium-difficile-toksin og fremgangsmåder dertil
US8758772B2 (en) 2011-11-04 2014-06-24 Abaxis, Inc. Peptides and methods for the detection of lyme disease antibodies
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
KR102451333B1 (ko) * 2018-10-22 2022-10-06 주식회사 엘지화학 마이크로비드 및 그 제조방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4767622A (en) * 1983-08-19 1988-08-30 University Of Illinois Method and materials for development of immunological responses protective against malarial infection
US4601903A (en) * 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US4888276A (en) 1986-06-26 1989-12-19 Minnesota Mining And Manufacturing Company Method and composition for the diagnosis of Lyme disease
US4721617A (en) 1986-08-14 1988-01-26 Regents Of The University Of Minnesota Vaccine against lyme disease
US5192540A (en) * 1988-04-19 1993-03-09 American Cyanamid Company Haemophilus influenzae type b oxidized polysaccharide-outer membrane protein conjugate vaccine
DE3818013A1 (de) 1988-05-27 1989-11-30 Henkel Kgaa Gewebeweichmachungsmittel
IT1223777B (it) * 1988-08-18 1990-09-29 Gevipi Ag Rubinetto a due uscite con inversore a depressione
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
DE3942728C1 (en) 1989-12-22 1991-05-23 Mikrogen Molekularbiologische Entwicklungs-Gmbh, 8000 Muenchen, De New immunologically active proteins derived from Borelia burgdorferiensity polyethylene vessel and a high density polyethylene sealing cap - useful as vaccine and for quick accurate diagnosis of Borelia infections
CA2072008C (en) * 1989-12-22 2003-01-28 Renate Fuchs Immunologically active proteins from borrelia burgdorferi, related test kits which contain these proteins and are suitable for detecting antibodies in test fluids, and the use of these proteins as vaccines against infections caused by borrelia strains
DE69122240T2 (de) 1990-03-05 1997-02-13 The United States of America, represented by the Secretary, U.S. Department of Commerce, Washington, D.C. Antigen-wirkende proteine von borrelia burgdorferi
EP1016416A3 (en) * 1990-07-06 2002-10-23 Wyeth Vaccine against lyme disease and a challenge model for evaluating vaccine efficacy

Also Published As

Publication number Publication date
SK279250B6 (sk) 1998-08-05
AU660178B2 (en) 1995-06-15
US6221363B1 (en) 2001-04-24
FI923175A (fi) 1993-01-12
EP0522560A3 (en) 1994-05-11
DE69231619T3 (de) 2007-07-12
ES2154633T3 (es) 2001-04-16
HRP950174B1 (en) 2001-08-31
JP2611095B2 (ja) 1997-05-21
EP0522560B2 (en) 2006-12-20
AU1934992A (en) 1993-01-14
EP0522560B1 (en) 2001-01-03
FI923175A0 (fi) 1992-07-09
NO922746D0 (no) 1992-07-10
CA2073486A1 (en) 1993-01-12
EP0522560A2 (en) 1993-01-13
US5530103A (en) 1996-06-25
ATE198489T1 (de) 2001-01-15
DE69231619T2 (de) 2001-05-31
SK217292A3 (en) 1998-08-05
HRP950174A2 (en) 1997-08-31
CZ217292A3 (en) 1993-01-13
HUT66525A (en) 1994-12-28
NO304546B1 (no) 1999-01-11
DE69231619D1 (de) 2001-02-08
CZ280743B6 (cs) 1996-04-17
JPH072696A (ja) 1995-01-06
HU219772B (hu) 2001-07-30
NO922746L (no) 1993-01-12
DK0522560T3 (da) 2001-03-05
HU9202289D0 (en) 1992-10-28
DK0522560T4 (da) 2007-04-10
SI9200143A (en) 1993-03-31
FI107334B (fi) 2001-07-13
MX9204078A (es) 1993-04-01
CA2073486C (en) 2002-07-02

Similar Documents

Publication Publication Date Title
SI9200143B (en) Method and composition for the prevention of lyme disease
UA40596C2 (uk) Композиція вакцини та спосіб її одержання
ES2157447T3 (es) Composicion de vacuna que comprende un antigeno de polisacarido conjugado adsorbido en fosfato de aluminio.
IL102639A (en) Compositions for inducing cytotoxic t lymphocyte responses
IL76777A (en) Inositoltriphosphates,their preparation and pharmaceutical compositions containing them
CA2218619A1 (en) Antibacterial-wound healing compositions and methods for preparing and using same
ATE100484T1 (de) Lagerstabile aufhellerformulierung.
PT979244E (pt) Derivados de ciclosporina, sua preparacao e composicoes farmaceuticas que os contem
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
MX9203667A (es) Sales de bis-dimetoximetil (trimetoxibencil)quinolino, su preparacion y composicines farmaceuticas que las contienen.
ES2042153T3 (es) Agentes para el tratamiento de estados de dolor graves y procedimientopara su preparacion.
GR3017267T3 (en) Antiacid compositions with prolonged gastric residence time.
ES2031904T3 (es) Procedimiento para producir una composicion farmaceutica que contiene ibuprofeno y hidroxido de aluminio.
AU7395791A (en) New uses of l-deprenyl and compositions for same
NO890226L (no) Organopolysiloxanmasser som kan fornettes til elastomererved avspaltning av alkoholer.
IL106968A0 (en) Potentiation of immunogenic response
NL300189I1 (nl) Acellulair vaccin.
NZ307055A (en) Immunostimulating-wound healing compositions and methods for preparing and using same
MX9401225A (es) Composicion de vacuna para prevenir la infeccion con influenza en humanos y metodo para su preparacion.
ATE265535T1 (de) Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen
CA2049325A1 (en) Peptide, immunogenic composition and vaccine or medicinal preparation; a method immunising a mammal against lhrh, and a method of improving the meat quality of pigs
DK0506772T3 (da) Farmaceutisk præparat indeholdende et phosphosukker
CA2078605A1 (en) Chicken anaemia agent vaccine
ES2079851T3 (es) Uso de il-4 para mejorar la respuesta inmunitaria frente a inmunogenos en vacunas.
RU93058633A (ru) Противоядие, способ его получения, фармацевтическая композиция, способ противодействия яду и комплект

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20050408